AstraZeneca said it is facing a tough 2010, with its drugs Arimidex for cancer and Pulmicort for asthma expected to lose sales as they face competition from ...
This year it faces the loss of exclusivity to its breast cancer treatment Arimidex and asthma medicine Pulmicort. The real panic will come as top sellers ...
15:38 - Buy-to-let mortgage specialist Paragon Group (PAG) claimed improvements in customer arrears helped it post a pre-tax profit of £13.2 million for the ...
Moreover, due to the potential loss of market exclusivity of Arimidex and Pulmicort Respules in the US, the company expects a mid single-digit decline in ...
Email this story